When will the HIV prevention pill go generic? Teva won’t say, pointing to a confidential settlement

A

mid widespread confusion over when the HIV prevention pill will go generic, a spokeswoman for Teva on Monday told STAT that the company has reached a confidential settlement controlling when it can enter the marketplace.

That spokeswoman, Elizabeth DeLuca, declined to say when Teva will launch its generic version of the drug currently sold by Gilead as Truvada, or how much it will charge.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

What is STAT Plus?

About the Author

Rebecca Robbins

Business Reporter

Rebecca covers the business of biopharma.

rebecca.robbins@statnews.com

@rebeccadrobbins

Tags

pharmaceuticals

policy

public health

sexual health

STAT Plus